RUCAPARIB CLINICAL OVERVIEW

UPDATED NOVEMBER 2017

Clovis Oncology believes that precision medicine — delivering the right treatment to the right patient — is the future of cancer therapy.

In our pursuit to improve the lives of people living with cancer, Clovis Oncology is committed to realizing the promise of precision medicines. We invest in robust clinical research and development programs to identify the patients who are most likely to benefit from our treatments. This research includes partnerships to develop companion diagnostics that will enable physicians to best guide patients to appropriate treatment.

ABOUT RUCAPARIB

Rucaparib is an oral, small molecule inhibitor of poly (ADP-ribose) polymerase (PARP) 1, 2 and 3. In December 2016, the U.S. Food and Drug Administration approved rucaparib (Rubraca®) to treat advanced ovarian cancer patients who have been treated with two or more chemotherapies and who have a deleterious germline or somatic BRCA mutation.

In October 2017, Clovis submitted a supplemental New Drug Application (sNDA) to the U.S. Food & Drug Association (FDA) for rucaparib as maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. The sNDA submission is based on data from the Phase 3 ARIEL3 trial.

Clovis' Marketing Authorization Application (MAA) for rucaparib to the European Medicines Agency for an ovarian cancer treatment indication is currently under review. Following a potential approval for the treatment indication, Clovis intends to submit a variation to the MAA for maintenance treatment.

Clovis is also exploring rucaparib as monotherapy and in combination in other solid tumor types, including BRCA-mutant and homologous recombination deficiency (HRD) patient populations. In addition to those described below, exploratory studies in other tumor types are also underway.

CURRENT CLOVIS-SPONSORED CLINICAL TRIALS INVESTIGATING RUCAPARIB

Indication	Trial Name, Phase	Population	Primary Endpoints	Status
Ovarian Cancer, Maintenance	**ARIEL3** Phase 3 *Study info*	Platinum-sensitive, recurrent, high-grade serous or endometrioid epithelial ovarian, primary peritoneal or fallopian tube cancer	• Progression-free survival	Complete Data supported October 2017 sNDA submission; view press release here.
	ATHENA Phase 3	Combination study of rucaparib and nivolumab in ovarian cancer	• TBD	Planned Spring 2018 Study part of Bristol-Meyers Squibb clinical collaboration; view press release here.
Ovarian Cancer, Treatment	**Study 10** Phase 1, 2 *Study info*	Patients with gBRCA mutation ovarian cancer or other solid tumor	• PK profile • Safety profile • Overall response rate	Complete Data supported 2016 FDA approval; view press release here.
	ARIEL2 Phase 2 *Study info*	Patients with relapsed, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer	• Progression-free survival • Overall response rate	Complete Data supported 2016 FDA approval; view press release here.
	ARIEL4 Phase 3 *Study info*	Relapsed, BRCA mutant, high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer	• Progression-free survival	Recruiting
Prostate Cancer	**TRITON2** Phase 2 *Study info*	Metastatic castration-resistant prostate cancer associated with homologous recombination deficiency following androgen receptor-targeted therapy and taxane-based chemotherapy	• Objective response rate • Prostate specific antigen (PSA) response	Recruiting
	TRITON3 Phase 3 *Study info*	Metastatic castration-resistant prostate cancer associated with homologous recombination deficiency following androgen receptor-targeted therapy	• Radiographic progression-free survival	Recruiting
Bladder Cancer	**ATLAS** Phase 2	Patients with locally advanced or metastatic urothelial carcinoma	• Objective response rate	Planned Spring 2018

Rucaparib is only FDA approved for the indication stated previously in the "About Rucaparib" section of this clinical overview. All other disease indications are investigational and therefore have not been proven safe or effective by any health authority.

The above chart reflects all Clovis-sponsored clinical trials. For more information on investigator-sponsored and partner-sponsored clinical trials, please visit www.clovisoncology.com/pipeline.

Visit **www.ClovisOncology.com** to learn more about Clovis Oncology and current rucaparib clinical trials underway. For information about enrollment status for any of these clinical trials, visit **www.ClinicalTrials.gov**.